Yan Leyfman: Comparing CAR T Cells, CAR NK Cells and CAR Macrophages in Glioma Therapy
Jan 31, 2025, 15:06

Yan Leyfman: Comparing CAR T Cells, CAR NK Cells and CAR Macrophages in Glioma Therapy

Yan Leyfman, Co-founder and executive director of MedNews Week, posted on LinkedIn about recent paper by Thomas Look et al., titled “CAR T cells, CAR NK cells, and CAR macrophages exhibit distinct traits in glioma models but are similarly enhanced when combined with cytokines” published on Cell Reports Medicine.

Authors: Thomas Look, Roman Sankowski, Manon Bouzereau, Serena Fazio, Miaomiao Sun, Alicia Buck, Niklas Binder, Maximilian Mastall, Francesco Prisco, Frauke Seehusen, Julia Frei, Conrad Wyss, Berend Snijder, Cesar Nombela Arrieta, Michael Weller, Steve Pascolo, Tobias Weiss

Yan Leyfman: Comparing CAR T Cells, CAR NK Cells and CAR Macrophages in Glioma Therapy

“Comparing CAR T Cells, CAR NK Cells and CAR Macrophages in Glioma Therapy.

Key Insights:

  • Different Strengths – CAR T, NK, and macrophages show distinct tumor-fighting abilities in glioma models.
  • Tumor Microenvironment Impact – Each immune cell type uniquely alters the tumor environment.
  • Cytokine Boost – Co-expressing cytokines enhances all CAR immune cells’ anti-tumor effects.

This study highlights the power of engineered immune cells and the need for multifaceted strategies to tackle glioblastoma.”